Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
Shah NR, Bhor M, Latremouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Kumar Singh M, Serra E, Davidson M, Xu L, Guerin A. Shah NR, et al. J Med Econ. 2020 Nov;23(11):1345-1355. doi: 10.1080/13696998.2020.1813144. Epub 2020 Sep 9. J Med Econ. 2020. PMID: 32815766 Free article.
Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP.
Atallah EL, Wei D, Latremouille-Viau D, Rossi C, Damon A, Ferreira G, Guérin A, Jadhav K. Atallah EL, et al. Among authors: latremouille viau d. Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):178-187.e2. doi: 10.1016/j.clml.2024.09.013. Epub 2024 Sep 26. Clin Lymphoma Myeloma Leuk. 2025. PMID: 39426944
Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.
Mayer EL, Smith ML, Guérin A, Latremouille-Viau D, Hazra NC, Meng Y, Qu W, Bellefleur R, Ganapathy V, Santarsiero L, Morlock R, Lustberg MB. Mayer EL, et al. Among authors: latremouille viau d. Breast Cancer Res Treat. 2025 May;211(1):121-130. doi: 10.1007/s10549-025-07627-4. Epub 2025 Feb 7. Breast Cancer Res Treat. 2025. PMID: 39915434 Free PMC article.
HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors - Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study.
Flynn KE, Clements J, DeMairo K, Hiller J, Wei D, Hazra NC, Constantinescu C, Meng Y, Latremouille-Viau D, Jadhav K, Marquez G, Yang D, Damon A, Sadek I, Guérin A, Schoenbeck K. Flynn KE, et al. Among authors: latremouille viau d. J Natl Compr Canc Netw. 2025 Mar 28;23(3.5):HSR25-174. doi: 10.6004/jnccn.2024.7251. J Natl Compr Canc Netw. 2025. PMID: 40154325 No abstract available.
Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis.
Tantravahi SK, Latremouille-Viau D, Desai R, Lee S, Paulose J, Geevarghese A, Guérin A, Seshasayee S, Chanpura M, Yen G. Tantravahi SK, et al. Among authors: latremouille viau d. J Health Econ Outcomes Res. 2025 Aug 15;12(2):66-74. doi: 10.36469/001c.142049. eCollection 2025. J Health Econ Outcomes Res. 2025. PMID: 40827257 Free PMC article.
HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia.
Flynn KE, Clements J, DeMairo K, Hiller J, Wei D, Hazra NC, Constantinescu C, Meng Y, Latremouille-Viau D, Jadhav K, Marquez G, Yang D, Damon A, Sadek I, Guérin A, Schoenbeck K. Flynn KE, et al. Among authors: latremouille viau d. J Natl Compr Canc Netw. 2025 Mar 28;23(3.5):HSR25-182. doi: 10.6004/jnccn.2024.7250. J Natl Compr Canc Netw. 2025. PMID: 40154303 No abstract available.
52 results